02  ·  Monthly Pulse

Oral Health Pulse

Top signals across five oral health segments, framed for consultant use. Ingredient innovation, whitening regulation, oral microbiome, and the fluoride vs hydroxyapatite debate — updated monthly by Brendan Walsh.

Edition 02  ·  May 2026

May 2026
Global oral care market
$48B
↑ 5.2% CAGR to 2029
Fastest growing segment
Whitening
↑ 8.1% yr — PAP leading premiumisation
Category challenger
nHAp
↑ Hydroxyapatite building RCT evidence
Regulatory watch
Charcoal
↓ ADA/BDA negative evidence active
Top five signals this month Ranked by consultant relevance
01
Caries prevention Regulatory
Hydroxyapatite vs fluoride — evidence closes the gap as the regulatory debate widens between markets

Nano-hydroxyapatite (nHAp) is now supported by multiple Cochrane-cited RCTs showing remineralisation efficacy comparable to fluoride in early-stage caries lesions. The EU allows biomimetic remineralisation claims; the FDA has not established an OTC monograph status for nHAp. Japanese oral care brands (Apagard, Regenerate) have built premium positions on HA. US brands face the choice of leading regulatory engagement or waiting for FDA clarity while watching European competitors define the premium tier.

So what: Advise US oral care clients to begin FDA pre-submission dialogue on nHAp now. The brand that achieves OTC monograph recognition first owns the premium caries prevention segment for a decade.
Tier 1PubMed — nHAp remineralisation RCT literature
Tier 1FDA — Topical Anticaries OTC Monograph docket
Tier 2NutraIngredients — HA oral care regulatory update

Consumer search and social signals also inform velocity rating.

Velocity
02
Periodontal Caries prevention
Oral microbiome probiotics gaining clinical credibility — BLIS K12 and M18 strains building RCT evidence base

S. salivarius K12 and M18 are demonstrating meaningful effects on oral pathogen suppression, halitosis reduction, and caries risk in accumulating RCT literature. The category is early but structurally sound — the oral microbiome is a genuinely distinct niche from the gut microbiome, with different strains, different delivery challenges (must survive in saliva, not reach the gut), and different clinical endpoints. The lozenge/tablet format is essential; toothpaste vehicle is incompatible with live organism survival.

So what: The oral probiotic category has no mainstream brand leader. First-mover with clinical substantiation and professional endorsement (dental hygienist recommendation channel) will define the category. Move in 2026.
Tier 1PubMed — BLIS K12/M18 clinical evidence
Tier 2NutraIngredients — Oral microbiome market update

Consumer search and social signals also inform velocity rating.

Velocity
03
Aesthetic / cosmetic Regulatory
PAP whitening validated as EU-compliant peroxide alternative — premium whitening brands accelerating adoption

Phthalimido-peroxy-caproic acid (PAP) delivers whitening comparable to low-concentration peroxide without the enamel sensitivity side effects. Critically, PAP is not restricted under EU cosmetics regulation (unlike hydrogen peroxide above 0.1%), making it the de facto whitening agent for European-compliant premium products. Spotlight Oral Care, HiSmile, and emerging DTC brands have built on PAP. The clinical evidence base is growing — 2025 RCT data confirms non-inferiority to carbamide peroxide 10% for shade improvement.

So what: PAP is the right whitening ingredient for brands operating across US and EU markets. The EU-compliant, enamel-safe narrative is a premium positioning differentiator that does not require regulatory compromise.
Tier 1PubMed — PAP whitening clinical evidence
Tier 1EU Cosmetics Regulation — peroxide restrictions
Tier 2Cosmetics Design Europe — PAP market adoption

Consumer search and social signals also inform velocity rating.

Velocity
04
Periodontal Caries prevention
Oral microbiome products market crosses $1.35B — double-digit CAGR to 2033 as category moves from niche to mainstream

The global oral microbiome products market reached $1.35 billion in 2025 and is projected at $3.6 billion by 2033 at 13.1% CAGR. BioGaia launched Prodentis FRESH BREATH lozenges combining BLIS strains with zinc. In January 2026 Fraunhofer commercialised a toothpaste ingredient that selectively inhibits periodontal pathogens while preserving the healthy microbiome, via spin-off PerioTrap. Pendulum Therapeutics expanded its Mayo Clinic clinical collaboration in April 2026 to cover oral and women's health microbiome applications.

So what: The oral probiotic category first-mover window is narrowing but still open in the US. A lozenge or tablet product using licensed BLIS K12/M18 strains with dental hygienist endorsement strategy can still define the category. The Fraunhofer/PerioTrap development suggests professional-grade selectivity is becoming feasible — watch for licensing opportunities.
Velocity
Tier 1PubMed — BLIS K12/M18 clinical evidence
Tier 2Grand View Research — Oral microbiome market $1.35B, 13.1% CAGR
Tier 2Grand View Research — PerioTrap and Pendulum developments

Consumer search and social signals also inform velocity rating.

05
Caries prevention
nHAp vs fluoride debate enters professional dental CE curriculum — accelerating mainstream adoption beyond consumer DTC

2026 dental professional CE programmes are now specifically addressing nano-hydroxyapatite vs fluoride comparisons, microbiome balance, and biomimetic technologies. Multiple DTC brands (Fygg, Boka) are actively positioning on nHAp. The oral care products market is forecast to reach $68.5 billion by 2033 at 5.1% CAGR, with premiumisation and hydroxyapatite lines cited as key growth drivers. The US still lacks OTC monograph status for nHAp, meaning brands must frame claims cosmetically — but FDA pre-submission dialogue is the strategic lever that changes this.

So what: When dental professionals include nHAp in their CE curriculum, consumer adoption moves from DTC-driven to professionally endorsed — a qualitative step change. The brand that initiates FDA monograph pre-submission dialogue in 2026 positions itself for drug-equivalent caries prevention claims before all US competitors.
Velocity
Tier 1PubMed — nHAp vs fluoride RCT evidence
Tier 1FDA — Topical anticaries OTC monograph docket
Tier 2Business Market Insights — Oral care market $68.5B forecast

Consumer search and social signals also inform velocity rating.

Ingredients to watch
Nano-hydroxyapatite (nHAp)
Biomimetic remineralisation building clinical parity with fluoride. EU regulatory advantage. US OTC monograph engagement is the strategic lever for first-mover position.
BLIS K12 / M18 oral probiotics
Specific strains, specific delivery format (lozenge/tablet), building RCT base. Category-defining window open. Professional channel (dental hygienist) is the recommendation gateway.
CPP-ACP (GC Tooth Mousse)
Strong professional evidence for early caries remineralisation. Consumer OTC market significantly underpenetrated relative to clinical evidence strength. Positioning opportunity.
Remineralising varnish (OTC)
High-concentration fluoride varnish moving toward consumer OTC in high-risk adult populations. Monitor FDA OTC monograph docket for professional-to-consumer pathway development.
Regulatory watch
UrgentCharcoal toothpaste — ADA and BDA both issued negative evidence statements. Enamel abrasivity confirmed. No ADA Seal achievable. Brands must exit or replace this format. No clinical defence available.
UrgentEU peroxide whitening restriction — hydrogen peroxide above 0.1% restricted in consumer products. Affects US brands operating in EU. PAP is the compliant whitening solution for pan-market brands.
WatchHydroxyapatite US status — FDA has not established OTC monograph status for nHAp. Claims must be carefully framed as cosmetic (not drug claims) until FDA engagement changes the regulatory picture.
MonitorEPA fluoride MCL reassessment — drinking water maximum contaminant level review is separate from toothpaste fluoride levels. Distinction matters for brand communications — toothpaste fluoride is unaffected.